Re Directorate-Replacemnt

Phytopharm PLC 22 September 2000 The issuer has made the following amendment to the 'Re Directorate' announcement released at 12:32 under RNS No 3859R. The following sentence was omitted from the announcement 'In addition, the Company advises that there are no matters under paragraph 6F2 (b) to (g) of the Listing Rules to be disclosed in relation to Dr Rees.' The full corrected version is shown below. ------------------------------------------------------------------- 22 September 2000 Phytopharm plc Board Appointment Phytopharm plc (PYM: London Stock Exchange) ('Phytopharm') is pleased to announce that Dr Daryl Rees has been appointed to the Board as Chief Scientific Officer. In this role he will have responsibility for the scientific strategy of Phytopharm's research and development programmes. Dr Rees joined Phytopharm in June 1999 from University College London where he was a Senior Lecturer in Clinical Pharmacology. Prior to this, Dr Rees gained 10 years' experience in the discovery and clinical development of medicines as a Senior Scientist at Wellcome and was part of a multi-disciplinary team involved in the discovery of the L-arginine-NO pathway. He is an Honorary Senior Lecturer in the Department of Medicine at University College London, a former Editor of the British Journal of Pharmacology, a member of the British Pharmacological Society, the British Hypertension Society, the European Shock Society and is Chairman designate of Huntingdon Local Research Ethics Committee. Commenting on his appointment, Richard Dixey, Chief Executive of Phytopharm, said: 'Daryl has a wealth of experience in the development of novel therapeutic agents and has played a key role in the successful progression of Phytopharm's lead clinical candidates for Alzheimer's disease (P58), Inflammatory Bowel Disease (P54), Eczema (P55) and Obesity (P57), as well as encouraging rapid development of the Company's preclinical portfolio. We are very pleased to see someone with Daryl's experience being appointed to Phytopharm's Board.' In addition, the Company advises that there are no matters under paragraph 6F2 (b) to (g) of the Listing Rules to be disclosed in relation to Dr Rees. Enquiries: Phytopharm plc Tel: 01480 437697 Richard Dixey, Chief Executive Financial Dynamics Tel: 0207 831 3113 David Yates / Sophie Pender-Cudlip NOTES TO EDITORS Phytopharm plc Phytopharm's business is to take both simple and complex mixtures derived from plant sources into full pharmaceutical development. The US Food and Drug Administration call such medicinal products 'Botanicals'. Botanical products are whole or partially purified extracts of medicinal plants in which the chemical composition is not fully characterised. Apart from being a new sector in the pharmaceutical market, Botanicals also act as an enabling technology to discover single chemical entities of clinical importance from plant sources. Phytopharm is the leading company in the development of botanical pharmaceuticals. It has developed a portfolio of 11 such products, nine of which are in the clinical evaluation phase. These products have been targeted in the five therapeutic categories of anti-inflammatory treatments, neurological disorders, dermatology, cancer and metabolic diseases. In 1997, Phytopharm was granted an Investigational New Drug (IND) approval in the US. The guidelines for the registration of botanical products have recently been published by the FDA. More information concerning Phytopharm's activities can be found on its Web site at http://www.phytopharm.co.uk.